Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1999 6
2001 1
2003 2
2004 2
2005 2
2006 2
2007 2
2008 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
No nerve growth factor response to treatment with memantine in adult rats.
Lang UE, Mühlbacher M, Hesselink MB, Zajaczkowski W, Danysz W, Danker-Hopfe H, Hellweg R. Lang UE, et al. Among authors: hesselink mb. J Neural Transm (Vienna). 2004 Feb;111(2):181-90. doi: 10.1007/s00702-003-0090-y. Epub 2003 Dec 29. J Neural Transm (Vienna). 2004. PMID: 14767721
SONU20176289, a compound combining partial dopamine D(2) receptor agonism with specific serotonin reuptake inhibitor activity, affects neuroplasticity in an animal model for depression.
Michael-Titus AT, Albert M, Michael GJ, Michaelis T, Watanabe T, Frahm J, Pudovkina O, van der Hart MG, Hesselink MB, Fuchs E, Czéh B. Michael-Titus AT, et al. Among authors: hesselink mb. Eur J Pharmacol. 2008 Nov 19;598(1-3):43-50. doi: 10.1016/j.ejphar.2008.09.006. Epub 2008 Sep 17. Eur J Pharmacol. 2008. PMID: 18822282
Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.
Smid P, Coolen HK, Keizer HG, van Hes R, de Moes JP, den Hartog AP, Stork B, Plekkenpol RH, Niemann LC, Stroomer CN, Tulp MT, van Stuivenberg HH, McCreary AC, Hesselink MB, Herremans AH, Kruse CG. Smid P, et al. Among authors: hesselink mb. J Med Chem. 2005 Nov 3;48(22):6855-69. doi: 10.1021/jm050148z. J Med Chem. 2005. PMID: 16250644
SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC, Glennon JC, Ashby CR Jr, Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG. McCreary AC, et al. Among authors: hesselink mb. Neuropsychopharmacology. 2007 Jan;32(1):78-94. doi: 10.1038/sj.npp.1301098. Epub 2006 May 17. Neuropsychopharmacology. 2007. PMID: 16710314
17 results